Bristol Myers Squibb annual free cash flow
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Bristol Myers Squibb Free Cash Flow (FCF) History (BMY)
Bristol Myers Squibb reported $12.85B in free cash flow for fiscal 2025, a decrease of 7.87% from the previous fiscal year, with a free cash flow margin of 26.65%.
View full Bristol Myers Squibb company overviewBristol Myers Squibb free cash flow by year
| Fiscal year | Period ended | Free cash flow | Change | Growth | FCF margin |
|---|---|---|---|---|---|
| 2025 | 2025-12-31 | $12.85B | −$1.10B | −7.87% | +26.65% |
| 2024 | 2024-12-31 | $13.94B | $1.29B | +10.20% | +28.87% |
| 2023 | 2023-12-31 | $12.65B | $703.0M | +5.88% | +28.11% |
| 2022 | 2022-12-31 | $11.95B | −$3.29B | −21.57% | +25.88% |
| 2021 | 2021-12-31 | $15.23B | $1.94B | +14.55% | +32.84% |
| 2020 | 2020-12-31 | $13.30B | $5.92B | +80.35% | +31.28% |
| 2019 | 2019-12-31 | $7.37B | $1.26B | +20.59% | +28.20% |
| 2018 | 2018-12-31 | $6.12B | $1.90B | +44.91% | +27.10% |
| 2017 | 2017-12-31 | $4.22B | $2.38B | +128.97% | +20.31% |
| 2016 | 2016-12-31 | $1.84B | $558.0M | +43.42% | +9.49% |
| 2015 | 2015-12-31 | $1.28B | −$1.34B | −50.99% | +7.76% |
| 2014 | 2014-12-31 | $2.62B | −$386.0M | −12.83% | +16.51% |
| 2013 | 2013-12-31 | $3.01B | −$3.38B | −52.95% | +18.36% |
| 2012 | 2012-12-31 | $6.39B | $1.92B | +42.92% | +36.28% |
| 2011 | 2011-12-31 | $4.47B | $406.0M | +9.98% | +21.06% |
| 2010 | 2010-12-31 | $4.07B | $732.0M | +21.95% | +20.87% |
| 2009 | 2009-12-31 | $3.33B | $569.0M | +20.57% | +17.73% |
| 2008 | 2008-12-31 | $2.77B | $456.0M | +19.74% | +15.61% |
| 2007 | 2007-12-31 | $2.31B | — | — | +14.79% |
Bristol Myers Squibb quarterly free cash flow
Q3.08
Q1.09
Q2.09
Q3.09
Q4.09
Q1.10
Q2.10
Q3.10
Q4.10
Q1.11
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Free cash flow | Change | YoY growth | FCF margin |
|---|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | $3.09B | −$468.0M | −13.16% | +23.80% |
| Q1 2026 | 2026-03-31 | $757.0M | −$937.0M | −55.31% | +6.59% |
| Q4 2025 | 2025-12-31 | $1.60B | −$2.46B | −60.50% | +12.83% |
| Q3 2025 | 2025-09-30 | $5.99B | $724.0M | +13.75% | +49.02% |
| Q2 2025 | 2025-06-30 | $3.56B | $1.49B | +72.29% | +28.98% |
| Q1 2025 | 2025-03-31 | $1.69B | −$856.0M | −33.57% | +15.12% |
| Q4 2024 | 2024-12-31 | $4.06B | $139.0M | +3.54% | +32.90% |
| Q3 2024 | 2024-09-30 | $5.27B | $858.0M | +19.46% | +44.29% |
| Q2 2024 | 2024-06-30 | $2.06B | $436.0M | +26.78% | +16.92% |
| Q1 2024 | 2024-03-31 | $2.55B | −$142.0M | −5.27% | +21.49% |
| Q4 2023 | 2023-12-31 | $3.92B | $962.0M | +32.50% | +34.17% |
| Q3 2023 | 2023-09-30 | $4.41B | $969.0M | +28.17% | +40.21% |
| Q2 2023 | 2023-06-30 | $1.63B | −$361.0M | −18.15% | +14.50% |
| Q1 2023 | 2023-03-31 | $2.69B | −$867.0M | −24.36% | +23.75% |
| Q4 2022 | 2022-12-31 | $2.96B | −$777.0M | −20.79% | +25.95% |
| Q3 2022 | 2022-09-30 | $3.44B | −$1.56B | −31.14% | +30.67% |
| Q2 2022 | 2022-06-30 | $1.99B | −$861.0M | −30.21% | +16.73% |
| Q1 2022 | 2022-03-31 | $3.56B | −$92.0M | −2.52% | +30.55% |
| Q4 2021 | 2021-12-31 | $3.74B | $665.0M | +21.65% | +31.18% |
| Q3 2021 | 2021-09-30 | $5.00B | $2.88B | +136.33% | +42.98% |
| Q2 2021 | 2021-06-30 | $2.85B | −$1.51B | −34.66% | +24.35% |
| Q1 2021 | 2021-03-31 | $3.65B | −$100.0M | −2.67% | +32.97% |
| Q4 2020 | 2020-12-31 | $3.07B | $1.14B | +59.17% | +27.76% |
| Q3 2020 | 2020-09-30 | $2.11B | −$252.0M | −10.65% | +20.06% |
| Q2 2020 | 2020-06-30 | $4.36B | $2.47B | +130.55% | +43.06% |
| Q1 2020 | 2020-03-31 | $3.75B | $2.56B | +216.27% | +34.79% |
| Q4 2019 | 2019-12-31 | $1.93B | −$1.33B | −40.89% | +24.29% |
| Q3 2019 | 2019-09-30 | $2.37B | $1.31B | +124.27% | +39.39% |
| Q2 2019 | 2019-06-30 | $1.89B | $1.03B | +120.26% | +30.16% |
| Q1 2019 | 2019-03-31 | $1.19B | $250.0M | +26.71% | +20.03% |
| Q4 2018 | 2018-12-31 | $3.27B | $2.40B | +278.33% | +54.66% |
| Q3 2018 | 2018-09-30 | $1.05B | −$396.0M | −27.29% | +18.54% |
| Q2 2018 | 2018-06-30 | $859.0M | −$477.0M | −35.70% | +15.06% |
| Q1 2018 | 2018-03-31 | $936.0M | $366.0M | +64.21% | +18.02% |
| Q4 2017 | 2017-12-31 | $863.0M | −$209.0M | −19.50% | +15.84% |
| Q3 2017 | 2017-09-30 | $1.45B | $388.0M | +36.50% | +27.62% |
| Q2 2017 | 2017-06-30 | $1.34B | $1.16B | +650.56% | +25.97% |
| Q1 2017 | 2017-03-31 | $570.0M | $1.04B | — | +11.56% |
| Q4 2016 | 2016-12-31 | $1.07B | $473.0M | +78.96% | +20.45% |
| Q3 2016 | 2016-09-30 | $1.06B | $773.0M | +266.55% | +21.60% |
| Q2 2016 | 2016-06-30 | $178.0M | $272.0M | — | +3.65% |
| Q1 2016 | 2016-03-31 | −$470.0M | −$960.0M | — | −10.70% |
| Q4 2015 | 2015-12-31 | $599.0M | $218.0M | +57.22% | +13.97% |
| Q3 2015 | 2015-09-30 | $290.0M | −$506.0M | −63.57% | +7.13% |
| Q2 2015 | 2015-06-30 | −$94.0M | −$1.04B | — | −2.26% |
| Q1 2015 | 2015-03-31 | $490.0M | −$9.0M | −1.80% | +12.13% |
| Q4 2014 | 2014-12-31 | $381.0M | −$829.0M | −68.51% | +8.95% |
| Q3 2014 | 2014-09-30 | $796.0M | −$133.0M | −14.32% | +20.30% |
| Q2 2014 | 2014-06-30 | $946.0M | −$466.0M | −33.00% | +24.33% |
| Q1 2014 | 2014-03-31 | $499.0M | $1.04B | — | +13.09% |
| Q4 2013 | 2013-12-31 | $1.21B | $549.0M | +83.06% | +27.25% |
| Q3 2013 | 2013-09-30 | $929.0M | −$3.52B | −79.11% | +22.85% |
| Q2 2013 | 2013-06-30 | $1.41B | $391.0M | +38.30% | +34.88% |
| Q1 2013 | 2013-03-31 | −$543.0M | −$807.0M | — | −14.17% |
| Q4 2012 | 2012-12-31 | $661.0M | −$773.0M | −53.91% | +15.77% |
| Q3 2012 | 2012-09-30 | $4.45B | $2.83B | +175.53% | +119.03% |
| Q2 2012 | 2012-06-30 | $1.02B | $2.0M | +0.20% | +22.98% |
| Q1 2012 | 2012-03-31 | $264.0M | −$142.0M | −34.98% | +5.03% |
| Q4 2011 | 2011-12-31 | $1.43B | −$36.0M | −2.45% | +26.29% |
| Q3 2011 | 2011-09-30 | $1.61B | $320.0M | +24.73% | +30.20% |
| Q2 2011 | 2011-06-30 | $1.02B | $51.0M | +5.27% | +18.75% |
| Q1 2011 | 2011-03-31 | $406.0M | $71.0M | +21.19% | +8.10% |
| Q4 2010 | 2010-12-31 | $1.47B | $322.0M | +28.05% | +28.76% |
| Q3 2010 | 2010-09-30 | $1.29B | −$10.0M | −0.77% | +26.97% |
| Q2 2010 | 2010-06-30 | $968.0M | $336.0M | +53.16% | +20.30% |
| Q1 2010 | 2010-03-31 | $335.0M | $84.0M | +33.47% | +6.97% |
| Q4 2009 | 2009-12-31 | $1.15B | — | — | +22.81% |
| Q3 2009 | 2009-09-30 | $1.30B | $78.0M | +6.36% | +27.23% |
| Q2 2009 | 2009-06-30 | $632.0M | — | — | +13.55% |
| Q1 2009 | 2009-03-31 | $251.0M | — | — | +5.81% |
| Q3 2008 | 2008-09-30 | $1.23B | — | — | +23.33% |
Bristol Myers Squibb free cash flow growth trends
Over the last five reported fiscal years, free cash flow declined from $13.30B to $12.85B, a compound annual decline of 0.69%. Bristol Myers Squibb's latest reported quarter, Q2 2026, generated $3.09B in free cash flow, a decrease of 13.16% year over year.
About the metric
What free cash flow means
Free cash flow is the cash a company generates from operations after capital expenditures. Positive FCF can fund dividends, buybacks, debt repayment, or reinvestment; negative FCF means capital spending exceeded operating cash flow for that period.
Calculation and source
How free cash flow is calculated
TickerStat calculates free cash flow as reported operating cash flow minus capital expenditures. FCF margin equals free cash flow divided by revenue. Fiscal periods can differ from calendar years, so the tables include exact period-end dates.
Review Bristol Myers Squibb source filings ↗Community posts
Bristol Myers reports deeper myeloma responses with iberdomide regimen
Bristol Myers Squibb ($BMY) presented Phase 3 EXCALIBER-RRMM results for iberdomide combined with daratumumab and dexamethasone in relapsed or refractory multiple myeloma. Among 420 evaluable patients, 41.1% achieved a complete response wit ...
Bristol Myers reports sustained two-year Sotyktu responses in psoriatic arthritis
Bristol Myers ($BMY) Squibb presented two-year follow-up from the POETYK PsA-2 extension study of Sotyktu in psoriatic arthritis. Among patients continuously receiving treatment, the ACR20 response rate was 76.2% using observed data and 65. ...
